In this episode of Epi Counts, host Bryan James talks to Maria Glymour, the incoming chair of the Department of Epidemiology at Boston University School of Public Health, about their shared area of research: the epidemiology of Alzheimer’s disease and dementia. In this conversation, they discuss the latest on how scientists are attempting to define Alzheimer’s disease biologically as a distinct concept from the dementia syndrome, as well as the controversies surrounding such a definition. They cover what the evidence says about what we can do to prevent dementia, and what aspects of Alzheimer’s and dementia make these conditions particularly difficult to study. Finally, they address the cautious excitement regarding the recent FDA approval of two new Alzheimer’s drugs that appear to target the underlying disease after decades of failed trials, and the societal, ethical, and financial implications that arise from the introduction of these therapies. Show notes: Alzheimer’s Association Facts & Figures report https://www.alz.org/alzheimers-dementia/facts-figures

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related